Candel Therapeutics, Inc. financial data

Symbol
CADL on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
117 Kendrick Street, Suite 450, Needham, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 351 % -73.5%
Debt-to-equity 150 % +142%
Return On Equity -206 % -285%
Return On Assets -82.5 % -150%
Operating Margin -27.8 K % -35%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 29.3 M shares +1.48%
Common Stock, Shares, Outstanding 29.3 M shares +1.48%
Entity Public Float 28.2 M USD -61%
Common Stock, Value, Issued 292 K USD +0.69%
Weighted Average Number of Shares Outstanding, Basic 29.2 M shares +0.96%
Weighted Average Number of Shares Outstanding, Diluted 29.2 M shares +0.96%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 125 K USD 0%
Research and Development Expense 23.1 M USD +11%
General and Administrative Expense 13.5 M USD -7.54%
Operating Income (Loss) -36.7 M USD -3.65%
Nonoperating Income (Expense) -705 K USD -108%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -37.4 M USD -39.9%
Earnings Per Share, Basic -1.29 USD/shares -40.2%
Earnings Per Share, Diluted -1.29 USD/shares -40.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25.7 M USD -56.6%
Assets, Current 27.1 M USD -56.1%
Property, Plant and Equipment, Net 2.96 M USD -27.7%
Operating Lease, Right-of-Use Asset 751 K USD -24.8%
Assets 31.2 M USD -53.6%
Accounts Payable, Current 472 K USD -20.3%
Employee-related Liabilities, Current 1.19 M USD -15.6%
Accrued Liabilities, Current 2.77 M USD -3.31%
Liabilities, Current 13.5 M USD +159%
Operating Lease, Liability, Noncurrent 837 K USD -38.6%
Liabilities 25.2 M USD -8.51%
Retained Earnings (Accumulated Deficit) -145 M USD -34.6%
Stockholders' Equity Attributable to Parent 5.98 M USD -84.9%
Liabilities and Equity 31.2 M USD -53.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.44 M USD +22%
Net Cash Provided by (Used in) Financing Activities -1.26 M USD
Net Cash Provided by (Used in) Investing Activities -7 K USD -137%
Common Stock, Shares Authorized 150 M shares 0%
Common Stock, Shares, Issued 29.5 M shares +1.47%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.7 M USD +10.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 26 M USD -56.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 549 K USD +9.8%
Deferred Tax Assets, Valuation Allowance 40.5 M USD +39%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 41 M USD +36.9%
Operating Lease, Liability 1.36 M USD -25.9%
Depreciation 251 K USD +9.13%
Payments to Acquire Property, Plant, and Equipment 7 K USD -94.9%
Lessee, Operating Lease, Liability, to be Paid 1.48 M USD -28.4%
Property, Plant and Equipment, Gross 5.3 M USD -2.84%
Operating Lease, Liability, Current 526 K USD +10.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 613 K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 450 K USD -24.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 115 K USD -48.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 415 K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 23.1 M USD +30.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 415 K USD -32.3%
Operating Lease, Payments 587 K USD +2.98%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 230 K USD +39.4%
Deferred Tax Assets, Net of Valuation Allowance 501 K USD -39.5%
Share-based Payment Arrangement, Expense 3.4 M USD +33.5%
Interest Expense 2.63 M USD +6.08%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%